MFDS Approves SK Bioscience COVID-19 Vaccine Phase 1 and 2 Clinical Trials

Types of COVID-19 Vaccines
[Image source=Yonhap News]

[Asia Economy Reporter Seongpil Cho] The Ministry of Food and Drug Safety announced on the 31st that it has approved the Phase 1 and 2 clinical trials of the novel coronavirus disease (COVID-19) vaccine 'GBP510' being developed by SK Bioscience.

This clinical trial aims to evaluate the safety and immunogenicity of GBP510 in healthy adults. Phase 2 will be conducted sequentially after Phase 1. With this, the number of COVID-19 related drugs approved for clinical trials and under development in South Korea has increased to 15 therapeutics (13 ingredients) and 6 vaccines.

GBP510 is a 'recombinant vaccine' created using genetic recombination technology to produce the surface antigen protein of the COVID-19 virus. The principle is that when the vaccine's surface antigen protein stimulates immune cells, neutralizing antibodies are formed, inducing an immune response. When the COVID-19 virus invades, the antibodies eliminate the virus.

Previously, SK Bioscience's recombinant vaccine 'NBP2001', which received Phase 1 clinical trial approval on the 23rd of last month, induces an immune response through the surface antigen protein of the COVID-19 virus. GBP510 differs in that its surface antigen protein binds with a specific protein forming an icosahedral nanostructure to induce an immune response.

This content was produced with the assistance of AI translation services.